Must See: Next 10 Yrs Belong to this Sector
Here is the latest financial fact sheet of ALKEM LABORATORIES. For more details, see the ALKEM LABORATORIES quarterly results and ALKEM LABORATORIES share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | -2.2 |
No. of shares | m | 119.57 |
1 Week | % | 1.7 |
1 Month | % | -3.4 |
1 Year | % | -10.2 |
52 week H/L | Rs | 3,720.0/2,835.0 |
No. of Mths Year Ending |
12 Mar-18* |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
5-Yr Chart Click to enlarge
|
---|
ALKEM LABORATORIES EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 2,468 | 2,265 | 2,720 | 3,150 | 4,068 | |
Low | Rs | 1,578 | 1,693 | 1,660 | 2,224 | 2,671 | |
Sales per share (Unadj.) | Rs | 533.8 | 615.3 | 697.9 | 741.4 | 889.4 | |
Earnings per share (Unadj.) | Rs | 53.4 | 64.7 | 96.1 | 135.3 | 140.5 | |
Diluted earnings per share | Rs | 53.4 | 64.7 | 96.1 | 135.3 | 140.5 | |
Cash flow per share (Unadj.) | Rs | 65.4 | 80.9 | 117.3 | 158.3 | 166.0 | |
Dividends per share (Unadj.) | Rs | 13.00 | 16.00 | 25.00 | 30.00 | 34.00 | |
Adj. dividends per share | Rs | 13.00 | 16.00 | 25.00 | 30.00 | 34.00 | |
Avg Dividend yield | % | 0.6 | 0.8 | 1.1 | 1.1 | 1.0 | |
Book value per share (Unadj.) | Rs | 406.7 | 454.8 | 515.1 | 616.8 | 722.4 | |
Adj. book value per share | Rs | 406.7 | 454.8 | 515.1 | 616.9 | 722.4 | |
Shares outstanding (eoy) | m | 119.57 | 119.57 | 119.57 | 119.57 | 119.57 | |
Price / Sales ratio | x | 3.8 | 3.2 | 3.1 | 3.6 | 3.8 | |
Avg P/E ratio | x | 37.9 | 30.6 | 22.8 | 19.9 | 24.0 | |
P/CF ratio (eoy) | x | 31.0 | 24.5 | 18.7 | 17.0 | 20.3 | |
Price / Book Value ratio | x | 5.0 | 4.4 | 4.3 | 4.4 | 4.7 | |
Dividend payout | % | 24.3 | 24.7 | 26.0 | 22.2 | 24.2 | |
Avg Mkt Cap | Rs m | 241,880 | 236,619 | 261,868 | 321,244 | 402,868 | |
Total wages/salary | Rs m | 11,916 | 13,625 | 15,055 | 16,210 | 19,627 |
ALKEM LABORATORIES INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 63,825 | 73,572 | 83,444 | 88,650 | 106,342 | |
Other income | Rs m | 1,154 | 877 | 1,042 | 2,332 | 1,627 | |
Total revenues | Rs m | 64,979 | 74,449 | 84,486 | 90,982 | 107,968 | |
Gross profit | Rs m | 10,089 | 11,148 | 14,734 | 19,424 | 20,380 | |
Depreciation | Rs m | 1,430 | 1,932 | 2,528 | 2,746 | 3,040 | |
Interest | Rs m | 553 | 546 | 651 | 589 | 524 | |
Profit before tax | Rs m | 9,260 | 9,547 | 12,598 | 18,421 | 18,443 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 2,876 | 1,810 | 1,105 | 2,243 | 1,640 | |
Profit after tax | Rs m | 6,384 | 7,736 | 11,493 | 16,178 | 16,803 | |
Gross profit margin | % | 15.8 | 15.2 | 17.7 | 21.9 | 19.2 | |
Effective tax rate | % | 31.1 | 19.0 | 8.8 | 12.2 | 8.9 | |
Net profit margin | % | 10.0 | 10.5 | 13.8 | 18.2 | 15.8 |
ALKEM LABORATORIES BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 40,132 | 42,044 | 55,057 | 69,233 | 84,337 | |
Current liabilities | Rs m | 23,833 | 22,175 | 32,446 | 36,041 | 48,053 | |
Net working cap to sales | % | 25.5 | 27.0 | 27.1 | 37.4 | 34.1 | |
Current ratio | x | 1.7 | 1.9 | 1.7 | 1.9 | 1.8 | |
Inventory Days | Days | 39 | 24 | 18 | 20 | 42 | |
Debtors Days | Days | 62 | 62 | 72 | 66 | 65 | |
Net fixed assets | Rs m | 29,968 | 32,844 | 35,073 | 34,825 | 43,245 | |
Share capital | Rs m | 239 | 239 | 239 | 239 | 239 | |
"Free" reserves | Rs m | 48,389 | 54,139 | 61,354 | 73,517 | 86,134 | |
Net worth | Rs m | 48,628 | 54,378 | 61,593 | 73,756 | 86,373 | |
Long term debt | Rs m | 1,307 | 2,313 | 739 | 279 | 94 | |
Total assets | Rs m | 70,100 | 75,006 | 90,130 | 104,114 | 127,599 | |
Interest coverage | x | 17.7 | 18.5 | 20.4 | 32.3 | 36.2 | |
Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
Sales to assets ratio | x | 0.9 | 1.0 | 0.9 | 0.9 | 0.8 | |
Return on assets | % | 9.9 | 11.0 | 13.5 | 16.1 | 13.6 | |
Return on equity | % | 13.1 | 14.2 | 18.7 | 21.9 | 19.5 | |
Return on capital | % | 19.7 | 17.8 | 21.3 | 25.7 | 21.9 | |
Exports to sales | % | 17.6 | 16.6 | 19.2 | 22.1 | 18.7 | |
Imports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 11,259 | 12,238 | 16,061 | 19,555 | 19,924 | |
Imports (cif) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Fx inflow | Rs m | 11,259 | 12,238 | 16,061 | 19,555 | 19,924 | |
Fx outflow | Rs m | 2,103 | 2,105 | 2,483 | 2,467 | 3,911 | |
Net fx | Rs m | 9,156 | 10,133 | 13,578 | 17,088 | 16,013 |
ALKEM LABORATORIES CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 2,660 | 7,797 | 5,851 | 12,649 | 11,110 | |
From Investments | Rs m | -3,572 | -3,164 | -7,414 | -9,985 | -14,351 | |
From Financial Activity | Rs m | 846 | -3,789 | 792 | -2,718 | 3,796 | |
Net Cashflow | Rs m | 1 | 823 | -731 | -17 | 580 |
Share Holding
Shareholding as on Dec 2022
|
Company Information
|
CHM: Basudeo N Singh | COMP SEC: Manish Narang | YEAR OF INC: 1973 | BSE CODE: 539523 | FV (Rs): 2 | DIV YIELD (%): 1.1 |
Read: ALKEM LABORATORIES 2021-22 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: AUROBINDO PHARMA CIPLA PIRAMAL ENTERPRISES LUPIN SUN PHARMA
Compare ALKEM LABORATORIES With: AUROBINDO PHARMA CIPLA PIRAMAL ENTERPRISES LUPIN SUN PHARMA
Asian share markets are struggling today in the wake of a slump on Wall Street after treasury secretary Janet Yellen rattled bank shares and the Federal Reserve pushed back against bets for interest rate cuts this year.